Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 82.73B 70.9B 66.33B 60.64B 114B 7,922B 116B 785B 305B 3,978B 311B 304B 13,161B P/E 2026 *
19.2x
P/E 2027 * 16.4x
Enterprise Value 75.86B 65.01B 60.82B 55.6B 105B 7,264B 106B 720B 280B 3,648B 285B 279B 12,068B EV / Sales 2026 *
4.48x
EV / Sales 2027 * 3.92x
Free-Float
71.06%
Yield 2026 *
0.47%
Yield 2027 * 0.54%
1 day-0.66%
1 week+2.80%
Current month+8.64%
1 month+26.29%
3 months+29.68%
6 months+7.29%
Current year+7.34%
1 week 815.38
Extreme 815.38
847
1 month 659.53
Extreme 659.53
847
Current year 591.52
Extreme 591.52
847
1 year 541
Extreme 541
847
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 85 01/06/1991
Date Insider Type Main position Quantity % Market Cap.
19/8/26 Fiscal year

General Counsel

33,583 0.0326%
18/8/26 Fiscal year

Chief Financial Officer

17,165 0.0167%
10/8/26 Fiscal year

Director

1,200 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
-0.66%+2.80%+40.55%-0.33% 82.73B
-4.30%+115.47%+412.13%+23.29% 55.45B
+2.68%+10.02%-19.76%-34.08% 57.94B
+1.42%+1.61%-0.67%+34.08% 52.57B
+1.05%+2.30%+10.60%+172.16% 48.94B
+0.62%+4.29%+56.57%-16.88% 32.23B
+0.13%+3.63%+50.49%+99.25% 25.94B
+0.60%+3.57%+0.15%+196.15% 22.1B
+2.70%-0.26%+59.68%+109.30% 16.55B
+0.16%+2.07%-1.27%+793.14% 16.13B
Average +1.10%+16.73%+60.85%+137.61% 41.06B
Weighted average by Cap. +1.08%+21.43%+72.21%+74.23%

Financials

2026 *2027 *
Net sales 16.92B 14.5B 13.57B 12.4B 23.41B 1,620B 23.65B 161B 62.42B 814B 63.53B 62.16B 2,692B 18.42B 15.78B 14.77B 13.5B 25.48B 1,764B 25.75B 175B 67.94B 886B 69.15B 67.66B 2,930B
Net income 4.77B 4.09B 3.83B 3.5B 6.6B 457B 6.67B 45.28B 17.61B 230B 17.92B 17.53B 759B 5.45B 4.67B 4.37B 3.99B 7.53B 521B 7.61B 51.66B 20.09B 262B 20.45B 20B 866B
Net Debt -6.87B -5.89B -5.51B -5.03B -9.5B -658B -9.6B -65.16B -25.34B -330B -25.79B -25.23B -1,093B -10.55B -9.04B -8.46B -7.74B -14.6B -1,011B -14.75B -100B -38.93B -507B -39.63B -38.77B -1,679B
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,410
Date Price Change Volume
24/08/26 USD 828.50 -0.66% 672,012
21/08/26 USD 834.04 +0.90% 786,921
20/08/26 USD 826.64 -1.69% 596,474
19/08/26 USD 840.84 +3.78% 750,445
18/08/26 USD 810.24 +0.53% 779,072
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
828.50USD
Average target price
840.43USD
Spread / Average Target
+1.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock